RxDoctor Payments Data

Jennifer King

Family · Parker, AZNPI 1780294793

Payments from drug & device makers

$679in general payments, 2019–2025

Across 30 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$135
  • Si-bone, Inc.$125
  • Bayer$54
  • Novartis$51
  • Novo Nordisk$45
  • Sanofi-aventis U.S. LLC$42
  • plus $227 from 11 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 60th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$2,093,659
Medicare patients
145
Services billed
2,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$126,497
XareltoRivaroxaban67$39,065
OzempicSemaglutide34$34,127
JardianceEmpagliflozin15$11,660
Atorvastatin Calcium567$8,617
Quetiapine Fumarate405$8,149
JanuviaSitagliptin Phosphate22$7,872
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,543
MyrbetriqMirabegron15$6,090
Levothyroxine Sodium441$5,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$5,140
Omeprazole220$5,095
Lisinopril305$4,712
Memantine Hcl155$4,658
Gabapentin289$4,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$126,497194 claims
Novo NordiskOzempic$45$34,12734 claims
AstraZenecaBreztri Aerosphere$135$7,54311 claims
Lilly USA, LLCOlanzapine$41$1,41243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,119 family providers in Arizona.

Other family in Parker

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →